TriSalus Life Sciences Inc
NASDAQ:TLSI
Intrinsic Value
TriSalus Life Sciences Inc is a US-based company operating in industry. [ Read More ]
The intrinsic value of one TLSI stock under the Base Case scenario is 4.61 USD. Compared to the current market price of 9.99 USD, TriSalus Life Sciences Inc is Overvalued by 54%.
Valuation Backtest
TriSalus Life Sciences Inc
Run backtest to discover the historical profit from buying and selling TLSI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
TriSalus Life Sciences Inc
| Current Assets | 20.9m |
| Cash & Short-Term Investments | 11.8m |
| Receivables | 3.6m |
| Other Current Assets | 5.5m |
| Non-Current Assets | 4.9m |
| PP&E | 3.3m |
| Intangibles | 1.1m |
| Other Non-Current Assets | 466k |
| Current Liabilities | 14.7m |
| Accounts Payable | 3.4m |
| Accrued Liabilities | 10.9m |
| Other Current Liabilities | 420k |
| Non-Current Liabilities | 37m |
| Other Non-Current Liabilities | 37m |
Earnings Waterfall
TriSalus Life Sciences Inc
|
Revenue
|
18.5m
USD
|
|
Cost of Revenue
|
-2.6m
USD
|
|
Gross Profit
|
15.9m
USD
|
|
Operating Expenses
|
-70.1m
USD
|
|
Operating Income
|
-54.2m
USD
|
|
Other Expenses
|
-9.1m
USD
|
|
Net Income
|
-63.3m
USD
|
Free Cash Flow Analysis
TriSalus Life Sciences Inc
TLSI Profitability Score
Profitability Due Diligence
TriSalus Life Sciences Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
TriSalus Life Sciences Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
TLSI Solvency Score
Solvency Due Diligence
TriSalus Life Sciences Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
TriSalus Life Sciences Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLSI Price Targets Summary
TriSalus Life Sciences Inc
According to Wall Street analysts, the average 1-year price target for TLSI is 16.32 USD with a low forecast of 16.16 USD and a high forecast of 16.8 USD.
Shareholder Return
TLSI Price
TriSalus Life Sciences Inc
| Average Annual Return | -2.21% |
| Standard Deviation of Annual Returns | 4.55% |
| Max Drawdown | -70% |
| Market Capitalization | 300.7m USD |
| Shares Outstanding | 30 098 300 |
| Percentage of Shares Shorted | 1.05% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
Contact
IPO
Employees
Officers
The intrinsic value of one TLSI stock under the Base Case scenario is 4.61 USD.
Compared to the current market price of 9.99 USD, TriSalus Life Sciences Inc is Overvalued by 54%.
You don't have any saved screeners yet
